Related references
Note: Only part of the references are listed.A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus
Willem de Winter et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2006)
Oral antidiabetic agents - Current role in type 2 diabetes mellitus
AJ Krentz et al.
DRUGS (2005)
Modeling the metabolic effects of terbutaline in β2-adrenergic receptor diplotypes
JJ Lima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers
SH Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2004)
Exendin-4 pharmacodynamics: Insights from the hyperglycemic clamp technique
DE Mager et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
H Agerso et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation
N Frey et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Metformin: An update
D Kirpichnikov et al.
ANNALS OF INTERNAL MEDICINE (2002)
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
MK Leabman et al.
PHARMACOGENETICS (2002)
The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study
TME Davis et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Metformin and lactic acidosis in diabetic humans
JD Lalau et al.
DIABETES OBESITY & METABOLISM (2000)
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
V Fonseca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
